Quotes 5-day view Real-time Euronext Bruxelles
01/27/2023
01/30/2023
01/31/2023
02/01/2023
02/02/2023
Date
346.6(c)
346.6(c)
347(c)
344.9(c)
343.6
Last
76 573
46 642
56 184
42 590
18 536
Volume
-1.20%
0.00%
+0.12%
-0.61%
-0.38%
Change
Estimated financial data (e) EUR USD
Sales 2022
415 M
453 M
453 M
Net income 2022
-790 M
-862 M
-862 M
Net cash position 2022
1 640 M
1 791 M
1 791 M
P/E ratio 2022
-24,8x
Yield 2022
-
Sales 2023
832 M
908 M
908 M
Net income 2023
-519 M
-566 M
-566 M
Net cash position 2023
1 438 M
1 570 M
1 570 M
P/E ratio 2023
-38,2x
Yield 2023
-
Capitalization
19 124 M
20 880 M
20 880 M
EV / Sales 2022
42,2x
EV / Sales 2023
21,3x
Nbr of Employees
650
Free-Float
100%
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune...
News in other languages on ARGENX SE
Analyst Recommendations on ARGENX SE
ETFs positioned on ARGENX SE ETFs and Trackers with Trackinsight
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ARGENX SE
Short Term Mid-Term Long Term Trends Bearish Bearish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Last Close Price
344,90 €
Average target price
463,59 €
Spread / Average Target
34,4%
Please enable JavaScript in your browser's settings to use dynamic charts.